Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,034 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.
Toyoda M, Shibahara I, Shigeeda R, Fujitani K, Tanihata Y, Hyakutake Y, Handa H, Komai H, Sato S, Inukai M, Hide T, Shimoda Y, Kanamori M, Endo H, Saito R, Matsuda KI, Sonoda Y, Kumabe T. Toyoda M, et al. J Neurooncol. 2024 Jun 5. doi: 10.1007/s11060-024-04687-2. Online ahead of print. J Neurooncol. 2024. PMID: 38839702
Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236.
Fujita S, Plianchaisuk A, Deguchi S, Ito H, Nao N, Wang L, Nasser H, Tamura T, Kimura I, Kashima Y, Suzuki R, Suzuki S, Kida I, Tsuda M, Oda Y, Hashimoto R, Watanabe Y, Uriu K, Yamasoba D, Guo Z, Hinay AA Jr, Kosugi Y, Chen L, Pan L, Kaku Y, Chu H, Donati F, Temmam S, Eloit M, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Suzuki Y; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Ikeda T, Tanaka S, Matsuno K, Fukuhara T, Takayama K, Sato K. Fujita S, et al. EBioMedicine. 2024 Jun 4;104:105181. doi: 10.1016/j.ebiom.2024.105181. Online ahead of print. EBioMedicine. 2024. PMID: 38838469
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
RECAP study group; Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. RECAP study group, et al. Among authors: toyoda m. Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38764356
Fine tuning of the net charge alternation of polyzwitterion surfaced lipid nanoparticles to enhance cellular uptake and membrane fusion potential.
Homma K, Miura Y, Kobayashi M, Chintrakulchai W, Toyoda M, Ogi K, Michinishi J, Ohtake T, Honda Y, Nomoto T, Takemoto H, Nishiyama N. Homma K, et al. Among authors: toyoda m. Sci Technol Adv Mater. 2024 Apr 10;25(1):2338785. doi: 10.1080/14686996.2024.2338785. eCollection 2024. Sci Technol Adv Mater. 2024. PMID: 38646148 Free PMC article.
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Among authors: toyoda m. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
1,034 results